Addressable Markets
LifePrint monetizes primarily through enterprise B2B data licensing, tapping into the fastest-growing segments of pharma R&D.
Global clinical trials services industry, 2025 (MarketsandMarkets). Range across major analysts: $52B–$93B. Pharma R&D spend is aggressively shifting toward decentralized, real-world models.
Source →Real-World Evidence (RWE) solutions market, 2025 (MarketsandMarkets). Projected to reach $10.83B by 2030 at 14.8% CAGR. Credible third-party estimates range $2.4B–$5.4B across firms; we cite the upper bound that reflects bundled solutions + services.
Source →Internal bottoms-up estimate of pharma + DeSci + longevity buyers willing to license cohort-level data on peptide / GLP-1 / hormone protocols at Year 3 scale. Methodology available under NDA.
Market figures are pinned to specific analyst sources with year. Range across Grand View Research, Mordor Intelligence, Precedence Research, and MarketsandMarkets is reported where applicable rather than cherry-picked.
The Consumer Demand Side
Our supply side is powered by the $6.8T global wellness economy (Global Wellness Institute, 2024 data; forecast $9.8T by 2029). Our addressable user base — Americans actively running self-directed GLP-1, peptide, or hormone protocols — is a fast-growing subset of that economy, anchored by the GLP-1 cohort below.
- ~31M US adults currently use GLP-1 medications (KFF, 2025)
- $8.7B US biohacking market (2025) (Spherical Insights, 2025)
- 600M+ wearable devices shipped globally in 2025 (IDC, 2025)
- Direct-to-consumer lab testing growing at 9–13% CAGR through 2030 (Mordor Intelligence, Precedence Research, 2025)
- FDA explicitly encourages RWE for label expansions and synthetic control arms (FDA RWE Framework, 2018 → ongoing guidance)